LIPI (lipase I) is a membrane-associated phospholipase that specifically hydrolyzes phosphatidic acid (PA) to generate 2-acyl lysophosphatidic acid (LPA), a potent bioactive lipid mediator, and fatty acids. Unlike other phospholipases, LIPI does not cleave other phospholipids including phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, or triacylglycerols, demonstrating remarkable substrate specificity. The enzyme localizes to the plasma membrane and participates in glycerophospholipid catabolism and PA biosynthetic processes. LIPI is classified as a cancer/testis antigen with restricted expression primarily in mammalian testis and tumor tissues 1. While the provided abstracts do not contain direct evidence of LIPI's role in human disease pathogenesis, they extensively document the clinical significance of the "Lung Immune Prognostic Index" (LIPI)—a prognostic biomarker combining lactate dehydrogenase and derived neutrophil-to-lymphocyte ratio—in predicting immunotherapy outcomes in lung cancer patients 2345. However, this LIPI biomarker is epidemiologically distinct from the LIPI gene product. Direct functional studies of the LIPI phospholipase in human disease remain absent from the provided literature.